Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $2.65 Million - $3.3 Million
20,007 New
20,007 $2.7 Million
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $2.91 Million - $3.34 Million
-21,668 Reduced 86.84%
3,283 $441,000
Q2 2022

Aug 15, 2022

BUY
$137.62 - $174.96 $3.43 Million - $4.37 Million
24,951 New
24,951 $3.82 Million
Q4 2021

Feb 14, 2022

SELL
$107.43 - $135.93 $2.37 Million - $3 Million
-22,097 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $1.19 Million - $1.35 Million
11,200 Added 102.78%
22,097 $2.38 Million
Q2 2021

Aug 16, 2021

SELL
$105.21 - $117.21 $888,708 - $990,072
-8,447 Reduced 43.67%
10,897 $1.23 Million
Q1 2021

May 17, 2021

BUY
$102.3 - $112.62 $1.12 Million - $1.24 Million
10,981 Added 131.3%
19,344 $2.09 Million
Q4 2020

Feb 16, 2021

SELL
$80.49 - $108.67 $1.29 Million - $1.74 Million
-16,049 Reduced 65.74%
8,363 $896,000
Q3 2020

Nov 16, 2020

BUY
$85.91 - $100.83 $2.1 Million - $2.46 Million
24,412 New
24,412 $2.14 Million
Q2 2020

Aug 14, 2020

SELL
$73.37 - $98.18 $1.27 Million - $1.69 Million
-17,254 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$64.5 - $97.79 $64,306 - $97,496
997 Added 6.13%
17,254 $1.3 Million
Q4 2019

Feb 14, 2020

BUY
$72.13 - $90.25 $1.17 Million - $1.47 Million
16,257 New
16,257 $1.44 Million
Q3 2018

Nov 14, 2018

SELL
$88.91 - $98.84 $392,715 - $436,576
-4,417 Closed
0 $0
Q2 2018

Aug 03, 2018

SELL
$89.78 - $106.23 $2.75 Million - $3.25 Million
-30,607 Reduced 87.39%
4,417 $409,000
Q4 2017

Jan 30, 2018

BUY
$89.56 - $98.21 $3.14 Million - $3.44 Million
35,024
35,024 $3.39 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $341B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Lmr Partners LLP Portfolio

Follow Lmr Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.